Long-acting triptorelin for the treatment of endometriosis

Wicharn Choktanasiri, W Choktanasiri, W Boonkasemsanti, Tul Sittisomwong, T Sittisomwong, Somboon Kunathikom, S Kunathikom, S Suksompong, Sirilak Suksompong, U Udomsubpayakul, Umaporn Udomsubpayakul, A Rojanasakul
International Journal of Gynecology & Obstetrics · 1996 · vol. 54(3) , pp. 237–243 · doi:10.1016/0020-7292(96)02698-7 · PMID:8889631 · W2058467806
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Monthly triptorelin injections effectively reduced endometriosis symptoms and disease severity, suppressed hormone levels, and showed tolerable side effects, though it caused minor changes in BMD and lipid profiles.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate the efficacy and adverse effects of monthly triptorelin injection for the treatment of endometriosis. METHODS: A multicenter clinical trial including 45 women with endometriosis, treated with triptorelin 3.75 mg i.m. every 4 weeks in six consecutive doses. The main outcome measures were symptom relief, reduction according to revised American Fertility Society (rAFS) scores, reduction in size of ovarian endometrioma, effects on hormone and lipid profiles, changes in bone mineral density (BMD), adverse effects, and return of menstruation. Data were analyzed using repeated measures analysis of variance and paired t-tests. RESULTS: Pain-related symptoms decreased in all cases after 8 weeks of treatment. Laparoscopic assessment revealed a reduction in rAFS scores in 21 out of 25 cases (mean pretreatment scores 43.44 +/- 5.75 vs. post-treatment scores 22.30 +/- 3.40, P < 0.001). The size of ovarian endometrioma decreased in eight of nine women but none disappeared. Serum luteinizing hormone, follicle-stimulating hormone and estradiol levels were effectively suppressed during treatment. A slight increase in cholesterol and triglyceride levels was observed but all values were within normal limits. After 24 weeks of treatment there was a slight decrease in BMD of total body, lumbar vertebrae and femoral neck but not radius. The main adverse effects included hot flushes, night sweating, vaginal dryness, headache, dizziness and nausea Menstruation returned 83.76 +/- 2.91 days after the last injection of triptorelin. CONCLUSION: Long-acting triptorelin is efficacious in the treatment of endometriosis and has tolerable side effects.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Endometriosis Ovarian Diseases Triptorelin Pamoate Adult Bone Density Delayed-Action Preparations Drug Administration Schedule Endometriosis Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Injections, Intramuscular Ovarian Diseases Ovarian Diseases Triptorelin Pamoate Triptorelin Pamoate Triptorelin Pamoate

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (10)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:57.821266+00:00
License: CC0 · commercial use OK